Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Leo Pharma"},{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Almirall"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$224.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eligo Bioscience"},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evommune"},{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Revel Pharmaceuticals"},{"orgOrder":0,"company":"Sequence Bio","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sequence Bio"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiondVax\u2019s Strategic Research Collaboration: Significant Progress Towards Development Of Innovative Nanosized Antibodies (NanoAbs) for Therapeutic Indications in Addition to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Concerto Biosciences"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Concerto Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline

              Details:

              The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.

              Lead Product(s): ENS-002

              Therapeutic Area: Dermatology Product Name: ENS-002

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Safar Partners

              Deal Size: $23.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scinai Immunotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BiondVax’s Strategic Research Collaboration: Significant Progress Towards Development Of Innovative Nanosized Antibodies (NanoAbs) for Therapeutic Indications in Addition...

              Details:

              The collaboration aims to generate and develop NanoAbs with the potential to answering needs underserved by currently approved conventional monoclonal antibody therapeutics as the NanoAbs exhibit potential for patient convenience, safety, and clinical outcomes, at lower costs.

              Lead Product(s): Alpaca‑derived Nanosized Antibody

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Max Planck Institute for Multidisciplinary Sciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sequence Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma

              Details:

              LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Leo Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revel Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

              Details:

              The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fibrosis (DNase).

              Lead Product(s): Enzyme Therapy

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kizoo Technology Capital

              Deal Size: $8.4 million Upfront Cash: Undisclosed

              Deal Type: Financing March 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evommune

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline

              Details:

              The financing will allow to advance four programs of Evommune in pipeline among which three of the compounds include IRAK4/TrkA, broadly inhibits innate inflammation; RORγt, treating inflammation; MRGPRX2, to treat chronic pruritus and fourth compound is a PKCtheta inhibitor.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Andera Partners

              Deal Size: $83.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eligo Bioscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million

              Details:

              Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.

              Lead Product(s): EB005

              Therapeutic Area: Dermatology Product Name: EB005

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: GSK

              Deal Size: $224.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration January 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Almirall

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines

              Details:

              The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: University of Dundee

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Leo Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma

              Details:

              Open Innovation Agreement with LEO Pharma A/S will screen novel VAP-1 inhibitor compounds discovered by Kubota Vision.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Kubota Vision Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY